JP2007186518A5 - - Google Patents

Download PDF

Info

Publication number
JP2007186518A5
JP2007186518A5 JP2007031781A JP2007031781A JP2007186518A5 JP 2007186518 A5 JP2007186518 A5 JP 2007186518A5 JP 2007031781 A JP2007031781 A JP 2007031781A JP 2007031781 A JP2007031781 A JP 2007031781A JP 2007186518 A5 JP2007186518 A5 JP 2007186518A5
Authority
JP
Japan
Prior art keywords
methyl
chlorophenyl
azetidin
difluorophenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007031781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007186518A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2007186518A publication Critical patent/JP2007186518A/ja
Publication of JP2007186518A5 publication Critical patent/JP2007186518A5/ja
Pending legal-status Critical Current

Links

JP2007031781A 2003-06-11 2007-02-13 置換３−アルキルおよび３−アルケニルアゼチジン誘導体 Pending JP2007186518A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47785003P 2003-06-11 2003-06-11
US60/477,850 2003-06-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006533655A Division JP3939744B2 (ja) 2003-06-11 2004-06-09 置換３−アルキルおよび３−アルケニルアゼチジン誘導体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011053759A Division JP2011144196A (ja) 2003-06-11 2011-03-11 置換３−アルキルおよび３−アルケニルアゼチジン誘導体

Publications (2)

Publication Number Publication Date
JP2007186518A JP2007186518A (ja) 2007-07-26
JP2007186518A5 true JP2007186518A5 (hu) 2008-04-17

Family

ID=33551769

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006533655A Expired - Fee Related JP3939744B2 (ja) 2003-06-11 2004-06-09 置換３−アルキルおよび３−アルケニルアゼチジン誘導体
JP2007031781A Pending JP2007186518A (ja) 2003-06-11 2007-02-13 置換３−アルキルおよび３−アルケニルアゼチジン誘導体
JP2011053759A Withdrawn JP2011144196A (ja) 2003-06-11 2011-03-11 置換３−アルキルおよび３−アルケニルアゼチジン誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006533655A Expired - Fee Related JP3939744B2 (ja) 2003-06-11 2004-06-09 置換３−アルキルおよび３−アルケニルアゼチジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011053759A Withdrawn JP2011144196A (ja) 2003-06-11 2011-03-11 置換３−アルキルおよび３−アルケニルアゼチジン誘導体

Country Status (20)

Country Link
US (2) US7485732B2 (hu)
EP (1) EP1636181A1 (hu)
JP (3) JP3939744B2 (hu)
KR (1) KR20060019587A (hu)
CN (1) CN1802351A (hu)
AU (1) AU2004252109B2 (hu)
BR (1) BRPI0411131A (hu)
CA (1) CA2527933C (hu)
CO (1) CO5650244A2 (hu)
EC (1) ECSP056207A (hu)
IL (1) IL172417A0 (hu)
IS (1) IS8146A (hu)
MA (1) MA27847A1 (hu)
MX (1) MXPA05013583A (hu)
NO (1) NO20060141L (hu)
NZ (1) NZ543451A (hu)
RU (1) RU2006100298A (hu)
UA (1) UA83230C2 (hu)
WO (1) WO2005000809A1 (hu)
ZA (1) ZA200509019B (hu)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
WO2004012671A2 (en) 2002-08-02 2004-02-12 Merck & Co., Inc. Substituted furo [2,3-b] pyridine derivatives
AU2003300967B2 (en) 2002-12-19 2009-05-28 Merck Sharp & Dohme Corp. Substituted amides
JP3939744B2 (ja) 2003-06-11 2007-07-04 メルク エンド カムパニー インコーポレーテッド 置換３−アルキルおよび３−アルケニルアゼチジン誘導体
JP2007510647A (ja) 2003-10-30 2007-04-26 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体調節剤としてのアラルキルアミン類
AU2006242219A1 (en) * 2005-05-02 2006-11-09 Merck & Co., Inc. Combination of dipeptidyl peptidase-IV inhibitor and a cannabinoid CB1 receptor antagonist for the treatment of diabetes and obesity
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
AR058199A1 (es) * 2005-11-28 2008-01-23 Merck & Co Inc Derivados de 3- alquilazetidina sustituidos con heterociclos
US7906652B2 (en) * 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
PE20071092A1 (es) * 2005-12-08 2007-12-10 Aventis Pharma Inc Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico
US7928058B2 (en) 2006-02-22 2011-04-19 Merck Sharp & Dohme Corp. Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008118141A2 (en) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
CA2707360A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Diphenyl substituted alkanes
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2008317482A1 (en) * 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Synthesis and crystalline forms of CB-1 antagonist/inverse agonist
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
JP2012504630A (ja) 2008-10-03 2012-02-23 シェーリング コーポレイション グルカゴン受容体アンタゴニストとしてのスピロイミダゾロン誘導体
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8592457B2 (en) 2008-10-30 2013-11-26 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010144664A1 (en) 2009-06-12 2010-12-16 Schering Corporation Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
KR101273566B1 (ko) * 2011-09-05 2013-06-11 한국과학기술연구원 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
US9682940B2 (en) 2015-08-25 2017-06-20 Janssen Pharmaceutica Nv Indazole derivatives useful as CB-1 inverse agonists
JP2021535202A (ja) * 2018-08-20 2021-12-16 ベッソール ファルマ、エルエルシー 新規カンナビノイドおよびカンナビノイド酸ならびにそれらの誘導体
EP3924058A1 (en) 2019-02-13 2021-12-22 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
IL300610A (en) 2020-08-18 2023-04-01 Merck Sharp ַ& Dohme Llc Bicycloheptane pyrrolidine compounds are orexin receptor agonists

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052383A (en) * 1974-10-30 1977-10-04 Schering Corporation N-diphenylalkyl-2-benzyl azacyclic compounds
US4133881A (en) * 1977-04-27 1979-01-09 A. H. Robins Company, Incorporated Azetidinyl acetonitrile and acetamide antiarrhythmia compositions and methods
US4242261A (en) * 1979-07-19 1980-12-30 A. H. Robins Company, Inc. Production of methylene-cycloamines
WO1997046511A1 (en) 1996-06-07 1997-12-11 Nps Pharmaceuticals, Inc. Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
WO1999004794A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
FR2783246B1 (fr) 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
KR100652994B1 (ko) * 1998-09-11 2006-11-30 아방티 파르마 소시에테 아노님 아제티딘 유도체, 이의 제조방법 및 이를 함유하는 약제
US6635661B2 (en) * 2000-05-25 2003-10-21 Sepracor Inc. Heterocyclic analgesic compounds and methods of use thereof
AU777760B2 (en) 1999-05-25 2004-10-28 Sepracor, Inc. Heterocyclic analgesic compounds and methods of use thereof
AU2001241927A1 (en) 2000-02-28 2001-09-12 Scios Inc. Inhibitors of p38-alpha kinase
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
FR2805817B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
GB0019006D0 (en) 2000-08-04 2000-09-20 Astrazeneca Ab Novel compounds
FR2814678B1 (fr) 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
GB0117387D0 (en) 2001-07-17 2001-09-05 Novartis Ag Organic compounds
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
FR2829027A1 (fr) 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
US7435736B2 (en) 2002-12-23 2008-10-14 Janssen Pharmaceutica, N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
EP1618105A1 (en) 2003-05-01 2006-01-25 Vernalis Research Limited Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders
MXPA05011670A (es) 2003-05-01 2005-12-15 Vernalis Res Ltd Derivados de azetidincarboxamida y su uso en el tratamiento de trastornos mediados por el receptor cb1.
JP3939744B2 (ja) * 2003-06-11 2007-07-04 メルク エンド カムパニー インコーポレーテッド 置換３−アルキルおよび３−アルケニルアゼチジン誘導体
CA2556565A1 (en) 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted azetidine compounds, their preparation and use as medicaments
US7906652B2 (en) * 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives

Similar Documents

Publication Publication Date Title
JP2007186518A5 (hu)
RU2006100298A (ru) Замещенные производные 3-алкил-и 3-алкенилазетидинов
RU2440330C2 (ru) ПРОИЗВОДНЫЕ 4-(2-АМИНО-1-ГИДРОКСИЭТИЛ)ФЕНОЛА, КАК АГОНИСТЫ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
JP4568113B2 (ja) Ｍｃｈ調節作用を有するジアリール置換環状尿素誘導体
US20090023791A1 (en) PH-dependent NMDA receptor antagonists
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
JP2008502614A5 (hu)
JP6276760B2 (ja) ４−アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬
JP2008507532A5 (hu)
EA009732B1 (ru) Диарильные и арилгетероарильные производные мочевины в качестве модуляторов 5-ht-рецептора серотонина, пригодные для профилактики и лечения связанных с ним заболеваний
JP2007522210A5 (hu)
RU2003119548A (ru) Фенилэтенил-или фенилэтенилпроизводные в качестве антагонистов глутаматного рецептора
JP2006525298A5 (hu)
JP2004520292A5 (hu)
ES2248413T3 (es) Derivados de 2-fenilaminoimidazolin fenil cetona sustituido como antagonistas de ip.
JP2012519179A5 (hu)
JP2008542365A5 (hu)
JP2007509959A (ja) トリアゾール化合物およびそれに関連する使用法
AU2002250256A1 (en) pH-dependent NMDA receptor antagonists
RU2006135084A (ru) Пентафторсульфанильные производные, их получение и применение в качестве фармацевтических агентов
JP2005506292A5 (hu)
RU2007127864A (ru) Производные n-[(4, 5-дифенил-3-алкил-2-тиенил)метил]амина (амид, сульфонамид, карбамат и карбамид) в качестве антагонистов рецепторов св1 каннабиноидов
CA2630040A1 (en) Heterocycle-substituted 3-alkyl azetidine derivatives
RU2008126248A (ru) Замещенные гетероциклами 3-алкилазетидиновые производные